We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00543010
First Posted: October 12, 2007
Last Update Posted: June 12, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
  Purpose

A study to evaluate the cardiac and metabolic effects of MK0767 in patients with Type 2 Diabetes.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).


Condition Intervention Phase
Diabetes Mellitus, Type 2 Drug: MK0767 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment

Further study details as provided by Merck Sharp & Dohme Corp.:

Enrollment: 247
Study Start Date: November 2002
Study Completion Date: November 2003
Primary Completion Date: November 2003 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • You are taking at least one medication for high blood sugar
  • Age 21 to 80

Exclusion Criteria:

  • History of Type 1 Diabetes Mellitus
  • Currently on estrogen replacement therapy regimen
  • Currently on a weight loss program with ongoing weight loss or taking medications for weight loss
  • Having surgery 30 days before starting the study
  • Have taken any other investigational drug in the past 90 days
  • Have Hepatitis B or C
  • Active liver or gallbladder disease
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00543010


Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00543010     History of Changes
Other Study ID Numbers: 0767-018
2007_644
First Submitted: October 5, 2007
First Posted: October 12, 2007
Last Update Posted: June 12, 2015
Last Verified: June 2015

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases